HDAC9 and cancer: Similar to dual BET/HDAC inhibitors, other single-molecule cotargeting BET and cancer key drivers have been reported, including dual PI3K/BET, CDK/BET, JAK2/BET, PLK1/BET and EGFR/BET inhibitors (reviewed in [95]).